Delivery Order SPE2DB20D1109-SPE2DB25FP38Z
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,555.23 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packaging) on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,124.59 to AmerisourceBergen Drug Corp for the supply of NURTEC ODT 75 mg tablets (8-count units) on April 24, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $36,599.31 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (quantity: 8 units) on November 3, 2025, with completion targeted for November 4, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The pharmaceutical will be delivered to the contractor's primary location in...
- The Defense Logistics Agency awarded a $23,518.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on September 18, 2025, with an ultimate completion date of September 19, 2025. This non-set-aside contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a $11.89K delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of NURTEC ODT 75 MG tablets (8-count units). This competitively awarded, firm fixed-price delivery order is set to be completed by July 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NURTEC ODT 75 mg tablets (8-count packages) under a firm fixed-price contract valued at $7,785.96. This non-set-aside award is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The pharmaceutical will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NURTEC ODT 75 mg tablets (8-pack quantity) valued at $14,310.29 under a firm fixed price contract. This competitive award, with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a $4,759.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on October 21, 2025, with completion scheduled for October 22, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $89,299.27 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of NURTEC ODT 75 mg tablets (8-count packaging) valued at $14,433.09. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The order will be fulfilled from the vendor's Conshohocken,...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP38ZDelivery Order
The Defense Logistics Agency awarded a $36,165.39 delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed at the contractor's corporate office in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order exemplifies AmerisourceBergen's role as a critical vendor within the DLA's pharmaceutical supply chain, supporting military and veteran healthcare systems. NURTEC ODT (rimegepant) is a prescription medication used for acute migraine treatment, reflecting the company's portfolio of specialty medications and neurological treatments supplied under its prime vendor contract. As a non-set-aside award, this transaction demonstrates the contractor's ability to compete successfully for federal medical supply requirements and aligns with DLA's strategy to maintain multiple pharmaceutical suppliers through comprehensive global support vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.2k | 7/14/25 |